Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers autologous or allogeneic hematopoietic cell transplantation (HCT) as a treatment of autoimmune diseases, including, but not limited to the following to be investigational:

- Multiple sclerosis
- Systemic sclerosis/scleroderma
- Systemic lupus erythematosus
- Juvenile idiopathic or rheumatoid arthritis
- Chronic inflammatory demyelinating polyneuropathy
- Type 1 diabetes.

Background/Overview
Most patients with autoimmune disorders respond to conventional therapies. However, these drugs are not curative, and a proportion of patients will have severe, recalcitrant, or rapidly progressive disease. It is in this group of patients with severe autoimmune disease that alternative therapies have been sought, including HCT.

Autoimmune Diseases
Autoimmune diseases represent a heterogeneous group of immune-mediated disorders, including MS, RA, SLE, systemic sclerosis/scleroderma, and CIDP. The National Institutes of Health (NIH) estimates that 5–8% of Americans have an autoimmune disorder.

The pathogenesis of autoimmune diseases is not well-understood but appears to involve underlying genetic susceptibility and environmental factors that lead to loss of self-tolerance, culminating in tissue damage by the patient’s own immune system (T cells).

Treatment
Immune suppression is a common treatment strategy for many of these diseases, particularly the rheumatic diseases (e.g., RA, SLE, and scleroderma). Most patients with autoimmune disorders respond to conventional therapies, which consist of anti-inflammatory agents, immunosuppressants, and immunomodulating drugs. However, these drugs are not curative, and a proportion of patients will have severe, recalcitrant, or rapidly progressive disease. It is in this group of patients with severe autoimmune disease that alternative therapies have been sought, including HCT. The primary concept underlying use of
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

HCT for these diseases is that ablating and “resetting” the immune system can alter the disease process, first inducing a sustained remission that possibly leads to cure.

Hematopoietic Cell Transplantation
Hematopoietic cell transplantation refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiation therapy. Hematopoietic cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the cells in it are antigenically “naïve” and thus, are associated with a lower incidence of rejection or graft-versus-host disease (GVHD).

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allogeneic HCT. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the class I and class II loci on chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

Autologous Cell Transplantation
The goal of autologous HCT in patients with autoimmune diseases is to eliminate self-reactive lymphocytes (lymphoablation) and generate new self-tolerant lymphocytes. This approach is in contrast to destroying the entire hematopoietic bone marrow (myeloablation), as is often performed in autologous HCT for hematologic malignancies. However, there is currently no standard conditioning regimen for autoimmune diseases and both lymphoablative and myeloablative regimens are used. The efficacy of the different conditioning regimens has not been compared in clinical trials.

Currently, for autoimmune diseases, autologous transplant is preferred over allogeneic, in part because of the lower toxicity of autotransplant relative to allogeneic, the GVHD associated with allogeneic transplant, and the need to administer post-transplant immunosuppression after an allogeneic transplant.

Allogeneic Cell Transplantation
The experience of using allogeneic HCT for autoimmune diseases is currently limited but has two potential advantages over autologous transplant. First, the use of donor cells from a genetically different individual could possibly eliminate genetic susceptibility to the autoimmune disease and potentially result in a cure. Second, there exists a possible graft-versus-autoimmune effect, in which the donor T cells attack the transplant recipient’s autoreactive immune cells.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

The U.S. FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Centers for Medicare and Medicaid Services (CMS)
There are numerous autoimmune diseases and the CMS has not issued a national coverage determination (NCD) for stem cell transplantation for each disease. A general NCD for stem cell transplantation (110.8.1) states the following:

a. Nationally Covered Indications

The following uses of allogeneic HSCT [hematopoietic stem-cell transplantation] are covered under Medicare:

i. Effective for services performed on or after August 1, 1978, for the treatment of leukemia, leukemia in remission, or aplastic anemia when it is reasonable and necessary,

ii. Effective for services performed on or after June 3, 1985, for the treatment of severe combined immunodeficiency disease (SCID) and for the treatment of Wiskott-Aldrich syndrome.

iii. Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study.

b. Nationally Non-Covered Indications

Effective for services performed on or after May 24, 1996, allogeneic HSCT is not covered as treatment for multiple myeloma.

2. Autologous Stem-Cell Transplantation (AuSCT)

a. Nationally Covered Indications

i. Effective for services performed on or after April 28, 1989, AuSCT is considered reasonable and necessary under §1862(a)(1)(A) of the Social Security Act (the Act) for the following conditions and is covered under Medicare for patients with:
   • Acute leukemia in remission who have a high probability of relapse and who have no HLA-matched;
   • Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
   • Recurrent or refractory neuroblastoma; or
   • Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor.

ii. Effective October 1, 2000, single AuSCT is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and,
- Adequate cardiac, renal, pulmonary, and hepatic function.

  iii. Effective for services performed on or after March 15, 2005, when recognized clinical risk factors are employed to select patients for transplantation, high-dose melphalan (HDM) together with AuSCT is reasonable and necessary for Medicare beneficiaries of any age group with primary amyloid light chain (AL) amyloidosis who meet the following criteria:
  - Amyloid deposition in 2 or fewer organs; and,
  - Cardiac left ventricular ejection fraction (EF) greater than 45%.

b. Nationally Non-Covered Indications
Insufficient data exist to establish definite conclusions regarding the efficacy of AuSCT for the following conditions:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma);
- Up to October 1, 2000, multiple myeloma;
- Tandem transplantation (multiple rounds of AuSCT) for patients with multiple myeloma;
- Effective October 1, 2000, non-primary AL amyloidosis; and,
- Effective October 1, 2000, thru March 14, 2005, primary AL amyloidosis for Medicare beneficiaries age 64 or older.

In these cases, AuSCT is not considered reasonable and necessary within the meaning of §1862(a)(1)(A) of the Act and is not covered under Medicare.

Rationale/Source
Recent reviews summarize the experience to date with HCT and autoimmune diseases.

As of March 2009, patients with an autoimmune disease registered in the European Group for Blood and Marrow Transplantation/European League Against Rheumatism (EBMT/EULAR) database who have undergone HCT include a total of 1,031 with the clinical indications of MS (n=379), systemic sclerosis (n=207), SLE (n=92), RA (n=88), juvenile idiopathic arthritis (n=70), idiopathic thrombocytopenic purpura (n=23), and Crohn’s disease (n=23).

Multiple Sclerosis
Only 1 randomized controlled trial (RCT) evaluating HCT for treatment of MS has been published, but this trial did not report clinical outcomes. No controlled trials with contemporaneous control groups were identified that reported clinical end points such as overall survival (OS), progression-free survival (PFS), or...
disability status as their primary outcomes. The 2015 RCT by Mancardi et al was originally designed as a phase 3 study reporting on disability progression. However, due to low patient enrollment, the protocol was amended as a phase 2 study with the primary outcome of cumulative number of new T2 magnetic resonance imaging (MRI) lesions in the 4 years after treatment. Eligibility for the trial was secondary progressive or relapsing-remitting MS, a documented worsening during the last year, and lack of response to conventional therapy. A total of 21 patients were randomized to autologous HCT (n=9) or medical therapy (mitoxantrone) (n=12). Follow-up data were not available on 4 patients; missing data was imputed in the intention-to-treat analysis of the primary outcome. The median number of new T2 MRI lesions was 2.5 in the HCT group and 8 in the conventional therapy group (rate ratio, 0.21; 95% confidence interval, 0.10 to 0.48, p<0.001). Among secondary outcomes, the annualized relapse rate was significantly lower in the HCT group (0.19) than in the conventional therapy group (0.6), but there was no statistically significant difference between groups in the rate of disease progression or change in disability status.

Systematic Reviews
A 2011 systematic review published evaluated the safety and efficacy of autologous HCT in patients with progressive MS refractory to conventional medical treatment. Eight case series met the inclusion criteria for the primary outcome of PFS, with a median follow-up of at least 2 years. An additional 6 studies were included for a summary of mortality and morbidity. For the 8 case series, there was substantial heterogeneity across studies. Most patients (77%) had secondary progressive MS, although studies also included those with primary progressive, progressive-relapsing, and relapse-remitting disease. Numbers of patients across studies ranged between 14 and 26. The studies differed in the types and intensities of conditioning regimens used prior to HCT, with 5 studies using an intermediate-intensity regimen and 3 using high-intensity regimens. All studies were rated as moderate quality. The estimated rate of long-term PFS of patients receiving intermediate-intensity conditioning regimen was 79.4% (95% CI, 69.9% to 86.5%) with a median follow-up of 39 months, while the estimate for patients who received a high-dose regimen was 44.6% (95% CI, 26.5% to 64.5%) at a median follow-up of 24 months. Of the 14 studies that reported on adverse events, 13 were case series; from these, 7 treatment-related deaths were recorded; 6 non-treatment-related deaths occurred, 5 associated with disease progression.

Nonrandomized Studies
A 2012 study by Shevchenko et al reported the results of a prospective, open-label, single-center study that analyzed the safety and efficacy of autologous HCT with reduced-intensity conditioning regimen in 95 patients with different types of MS. Patients underwent early, conventional, and salvage/late transplantation. Efficacy was evaluated based on clinical and quality-of-life (QOL) outcomes. No transplantation-related deaths were observed. All patients, except 1, responded to treatment. At long-term follow-up (mean, 46 months), the overall clinical response in terms of disease improvement or stabilization was 80%. The estimated PFS at 5 years was 92% in the group after early transplant and 73% in the group after conventional/salvage transplant (p=0.01). No active, new, or enlarging lesions on MRI were found in patients without disease progression. All patients who did not have disease progression were off therapy throughout the posttransplantation period. HCT was accompanied by a significant improvement in QOL, with statistically significant changes in most QOL parameters (p<0.05). A 2015 subsequent publication
reported on 64 patients participating in this trial who had at least 36 months of follow-up (median, 62 months). (Another 35 patients had shorter follow-up and the remainder were lost to follow-up.) Thirty (47%) of the 64 patients improved at least 0.5 point on the EDSS score compared with baseline. Among the other patients, 29 (45%) were stable and 5 (7%) experienced worsening disease.

In 2012, Mancardi et al reported on 74 consecutive patients with MS treated using autologous HCT with an intermediate-intensity conditioning regimen in the period from 1996 to 2008. Thirty-six patients had secondary progressive disease and 25 had relapsing-remitting MS. Clinical and MRI outcomes were reported. Median follow-up was 48.3 months (range, 0.8-126 months). Two patients (2.7%) died from transplant-related causes. After 5 years, 66% of patients remained stable or improved. Among patients with a follow-up longer than 1 year, 8 (31%) of 25 subjects with a relapsing-remitting course had a 6- to 12-month confirmed EDSS score improvement greater than 1 point after HCT compared with 1 (3%) of 36 patients with a secondary progressive disease course (p=0.009). Among the 18 cases with a follow-up longer than 7 years, 8 (44%) remained stable or had a sustained improvement, while 10 (56%), after an initial period of stabilization or improvement (median duration, 3.5 years), showed a slow disability progression.

A 2015 single-center case series by Burt et al reported on 151 patients, 123 with relapsing-remitting MS and 28 with secondary progressive MS. Patients were treated with nonmyeloablative HCT between 2003 and 2014. Six patients were not included in the outcome analysis. The remaining 145 patients were followed for a median of 2 years (range, 6 months to 5 years). There were no treatment-related deaths. The primary outcome was change in the EDSS score. A decrease of at least 1.0 point was considered significant improvement and an increase of at least 1.0 point was considered significant progression. There was statistically significant improvement in EDSS score for the group as a whole compared with the pretransplant mean score of 4.0, decreasing to a mean EDSS score of 2.5 at 3, 4, and 5 years. In post hoc analysis, patients most likely to have statistically significant improvements in EDSS score were those with relapsing-remitting MS, with duration of disease of 10 years or less, and those without sustained fever during HCT.

Several studies have focused on patients with aggressive MS. In 2011, Fassas et al reported the long-term results of a single-center study that investigated the effect of HCT in the treatment of MS. The authors reported, after a median follow-up period of 11 years (range, 2-15 years), on the clinical and MRI outcomes of 35 patients with aggressive MS treated with HCT. Disease PFS at 15 years was 44% for patients with active central nervous system disease and 10% for those without (p=0.01); median time to progression was 11 years (range, 0-22 years) and 2 years (range, 0-6 years), respectively. Improvements by 0.5 to 5.5 (median, 1) EDSS points were observed in 16 cases, lasting for a median of 2 years. In 9 of these patients, EDSS scores did not progress above baseline scores. Two patients died, at 2 months and 2.5 years, from transplant-related complications. Gadolinium-enhancing lesions were significantly reduced after mobilization but were maximally and persistently diminished post-HCT.
A 2014 multicenter case series by Burman et al reported on 48 patients with aggressive relapsing-remitting MS, defined as disease with high relapse frequency, and who failed conventional therapy. Patients underwent autologous HCT. At the 5-year follow-up, relapse-free survival was 87% and the EDSS score PFS (EDSS deterioration of <0.5 points) was 77%. The rate of disease-free survival (no relapses, no new MRI lesions, no EDSS score progression) was 68%.

In 2016, Atkins et al published a phase 2 trial investigating the use of immunoablation and autologous HCT for the treatment of aggressive MS. Inclusion criteria were: poor prognosis, ongoing disease activity, and EDSS score between 3.0 and 6.0. Twenty-four patients enrolled, and had a median follow-up of 6.7 years (range, 4-13 years). One patient died of transplant-related complications (hepatic necrosis following sepsis). The primary outcome (activity-free survival at 3 years after transplantation) was 70% (95% CI, 47% to 84%). During the extended follow-up period, without the use of disease-modifying drugs, no signs of central nervous system inflammation were detected clinically or radiologically. Clinical relapses did not occur among the 23 surviving patients in 179 patient-years of follow-up. Thirty-three percent of the patients experienced grade 2 toxic effects and 58% experienced grade 1 transplantation-related toxic effects.

Results from the High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT-MS) trial were published in 2017 by Nash et al. The trial evaluated 24 patients with MS who were treated with high-dose immunosuppression and autologous HCT. The median follow-up was 62 months (range, 12-72 months). Outcomes were PFS (91%; 90% CI, 75% to 97%), clinical relapse-free survival (87%; 90% CI, 69% to 95%), and MRI activity-free survival (86%; 90% CI, 68% to 95%). Patients experienced high rates of adverse events: 92% had grade 3 and 100% had grade 4 adverse events. The majority of adverse events occurred between the start of conditioning to day 29 in the trial.

Section Summary: Multiple Sclerosis
Evidence for the use of HCT in patients with MS consists of an RCT and many single-arm studies. The RCT compared HCT (n=9) with mitoxantrone (n=12). The primary outcome was the number of new T2 lesions detected by MRI. The HCT group developed statistically fewer lesions than the mitoxantrone group. Outcomes in the single-arm studies included PFS, relapse-free survival, disease activity-free survival, disease stabilization, number of new lesions, and improvements in EDSS scores. While improvements were seen in all outcomes compared with baseline, there were no comparative treatments. Adverse event rates were high, and most studies reported treatment-related deaths.

Systemic Sclerosis/Scleroderma
Systematic Reviews
In 2015, van Laar et al conducted a systematic review of evidence on the use of HCT for treating poor-prognosis systemic sclerosis. They identified 3 RCTs comparing HCT with the standard of care (cyclophosphamide): a phase 2 trial and a completed phase 3 trial, both of which are described in the Randomized Controlled Trial section, plus a phase 3 trial (Scleroderma: Cyclophosphamide or Transplantation [SCOT]). SCOT has been completed and results presented at a 2016 American College of...
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy #  00050
Original Effective Date:  01/28/2002
Current Effective Date:  12/20/2017

Rheumatology conference. Results have not been published at the time of this update. Reviewers concluded that there is evidence HCT can result in significant improvements in skin thickness and functional outcomes. However, HCT is associated with serious toxicities that can be fatal. Additional trials are needed to assess how to reduce toxicity and to determine which patients with scleroderma would benefit most from HCT.

A review in 2011 by Milanetti et al summarized 8 phase 1 and 2 clinical studies using autologous HCT to treat systemic sclerosis. The number of patients in each study ranged from 6 to 57. The proportion of patients across the studies achieving a 25% decrease in the Rodnan Skin Score (RSS) ranged from 60% to 100%. Pooled analyses were not conducted.

Randomized Controlled Trials
Results of the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial (ISRCTN54371254) were published in 2014. ASTIS was a phase 3 RCT conducted in 10 countries at 29 centers with access to an EBMT-registered transplant facility. A total of 156 patients were recruited between March 2001 and October 2009. Patients were eligible if they were between 18 and 65 years of age; had diffuse cutaneous systemic sclerosis according to American Rheumatism Association criteria, with maximum duration of 4 years; minimum modified Rodnan Skin Score (RSS) of 15 (range, 0-51; higher scores indicate more severe skin thickening); and involvement of heart, lungs, or kidneys. Patients were randomly allocated to receive high-dose chemotherapy (intravenous cyclophosphamide 200 mL/kg over 4 consecutive days and intravenous rabbit antithymocyte globulin 7.5 mg/kg total dose over 3 consecutive days) followed by CD34+ selected autologous HCT support (n=79) or 12 monthly treatments with intravenous pulsed cyclophosphamide (750 mg/m²). Median follow-up was 5.8 years (interquartile range, 4.1-7.8 years). The primary end point was event-free survival, defined as the time in days from randomization until the occurrence of death due to any cause or the development of persistent major organ failure (heart, lung, kidney). Main secondary end points included treatment-related mortality, toxicity, and disease-related changes in modified RSS, organ function, body weight, and QOL scores. The internal validity (risk of bias) of ASTIS was assessed according to the U.S. Preventive Services Task Force criteria for randomized trials. The study was rated as "poor" quality according to this framework because of 2 fatal flaws: outcome assessment was not masked to patients or assessors, and 18 (24%) of 75 of the control group discontinued intervention because of death, major organ failure, adverse events, or nonadherence. Furthermore, the trial design permitted crossover after the second year, but whether any patients did so and were analyzed as such is not mentioned. Finally, the authors reported that the use of unspecified concomitant medications or other supportive care measures were allowed at the discretion of the investigators, adding further uncertainty to the results.

Of the 53 primary end point events recorded, 22 were in the HCT group (19 deaths, 3 irreversible organ failures; 8 patients died of treatment-related causes in the first year, 9 of disease progression, 1 of cerebrovascular disease, 1 of malignancy) and 31 were in the control group (23 deaths, 8 irreversible organ failures [7 of whom died later]; 19 patients died of disease progression, 4 of cardiovascular disease, 5 of malignancy, 2 of other causes). The data showed patients treated with HCT experienced more events in the
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

first year but appeared to have better long-term event-free survival than the controls, with Kaplan-Meier curves for OS crossing at about 2 years after treatment with OS at that time estimated at 85%. According to the Kaplan-Meier curves, at 5 years, OS was an estimated 66% in the control group and an estimated 80% in the HCT group (p value unknown). Time-varying hazard ratios (modeled with a treatment by time interaction) for event-free survival were 0.35 (95% CI, 0.15 to 0.74) at 2 years and 0.34 (95% CI, 0.16 to 0.74) at 4 years, supporting a benefit of HCT compared with pulsed cyclophosphamide. Severe or life-threatening grade 3 or 4 adverse events were reported in 51 (63%) of the HCT group and 30 (37%) by intention-to-treat, (p=0.002) of the control group.

An open-label, randomized, controlled phase 2 trial (ASSIST; 2011) evaluated the safety and efficacy of autologous nonmyeloablative HCT compared with the standard of care (cyclophosphamide). Nineteen consecutively enrolled patients less than 60 years of age with diffuse systemic sclerosis, modified RSS greater than 14, and organ involvement or restricted skin involvement (modified RSS, <14) but coexistent pulmonary involvement were randomized 1:1 to HCT, intravenous cyclophosphamide 200 mg/kg, plus rabbit antithymocyte globulin or to intravenous cyclophosphamide 1.0 g/m² once per month for 6 months. The primary outcome was an improvement at 12 months, which was defined as a decrease in modified RSS (<25% for those with initial modified RSS >14) or an increase in forced vital capacity of more than 10%. Patients in the control group with disease progression (>25% increase in modified RSS or decrease of >10% in forced vital capacity) despite treatment with cyclophosphamide could switch to HCT 12 months after enrollment. No deaths occurred in either group during follow-up. Patients allocated to HCT (n=10) improved at or before the 12-month follow-up compared with none of the 9 patients allocated to cyclophosphamide (p=0.001). Treatment failure (ie, disease progression without interval improvement), occurred in 8 of 9 controls but did not occur in any of the 10 patients treated by HCT (p=0.001). After long-term follow-up (mean, 2.6 years) of patients allocated to HCT, all but 2 patients had sustained improvement in modified RSS and forced vital capacity, with a longest follow-up of 60 months. Seven patients allocated to receive cyclophosphamide switched treatment groups at a mean of 14 months after enrollment and underwent HCT without complication; all improved after HCT. Four of these patients, followed for at least 1 year, had a mean (standard deviation [SD]) decrease in modified RSS from 27 (SD=15.5) to 15 (SD=7.4), an increase in forced vital capacity from 65% (20.6%) to 76% (26.5%), and an increase in total lung capacity from 81% (14.0%) to 88% (13.9%). Data for 11 patients with follow-up to 2 years after HCT suggested that the improvements in modified RSS (p<0.001) and forced vital capacity (p<0.03) persisted.

Nonrandomized Studies
Vonk et al (2008) reported the long-term results of 28 patients with severe diffuse cutaneous systemic sclerosis who underwent autologous HCT from 1998 to 2004. There was 1 transplant-related death and 1 death due to progressive disease, leaving 26 patients for evaluation. After a median follow-up of 5.3 years (range, 1-7.5 years), 81% (n=21/26) of the patients demonstrated a clinically beneficial response. Skin sclerosis was measured with a modified RSS, and a significant (ie, >25%) decrease (ie, improvement) was achieved in 19 of 26 patients after 1 year and in 15 of 16 after 5 years. At study baseline, 65% of patients had significant lung involvement; all pulmonary function parameters remained stable after transplant at 5- and 7-year follow-ups. Based on the World Health Organization Performance Status, which reflects the

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
effect of HCT on the combination of functional status, skin, lung, heart, and kidney involvement, the percentage of patients with a Performance Status score of 0 increased to 56% from 4% at baseline. Estimated survival at 5 years was 96.2% (95% CI, 89% to 100%) and at 7 years was 84.8% (95% CI, 70.2% to 100%); and event-free survival (survival without mortality, relapse, or progression of systemic sclerosis resulting in major organ dysfunction) was 64.3% (95% CI, 47.9% to 86%) at 5 years and 57.1% (95% CI, 39.3% to 83%) at 7 years. For comparison, an international meta-analysis published in 2005 estimated the 5-year mortality rate in patients with severe systemic sclerosis at 40%.

Nash et al (2007) reported on the long-term follow-up of 34 patients with diffuse cutaneous systemic sclerosis with significant visceral organ involvement who were enrolled in a multi-institutional pilot study between 1997 and 2005 and underwent autologous HCT. Of the 34 patients, 27 (79%) survived 1 year and were evaluable for response (there were 8 transplant-related deaths and 4 systemic sclerosis-related deaths). Of the 27 evaluable patients, 17 (63%) had sustained responses at a median follow-up of 4 years (range, 1-8 years). Skin biopsies showed a statistically significant decrease in dermal fibrosis compared with baseline (p<0.001) and, in general, lung, heart, and kidney function remained stable. Overall function as assessed in 25 patients using the Disability Index of the modified Health Assessment Questionnaire showed improvement in 19, and disease response was observed in the skin of 23 of 25 and lungs of 8 of 27 patients. Estimated OS and PFS rates were both 64% at 5 years.

Henes et al (2012) reported on 26 consecutive patients with systemic sclerosis scheduled for autologous HCT between 1997 and 2009. The main outcome variable was response to treatment (reduction of modified RSS by 25%) at 6 months. Secondary end points were transplant-related mortality and PFS. At 6 months, significant skin and lung function improvement assessed on the modified RSS was achieved in 78.3% of patients. Overall response rate was 91%, and some patients even improved after month 6. Three patients died between mobilization and conditioning treatment—two due to severe disease progression and one treatment-related. Seven patients relapsed during the 4.4 years of follow-up. PFS was 74%. Four patients died during follow-up, with the most frequent causes of death being pulmonary and cardiac complications of systemic sclerosis.

Section Summary: Systemic Sclerosis/Scleroderma
Evidence for the use of HCT in patients with systemic sclerosis/scleroderma consists of 3 RCTs and nonrandomized studies. Two (one with 19 patients, the other with 156 patients) have published results, and reported statistical significant improvements in clinical outcomes (skin thickness, forced vital capacity). The larger trial (ASTIS) also reported improved OS. However, HCT can result in serious adverse events due to toxicity. The third RCT, completed and expected to be published soon, employed a different transplant regimen. Additional information on the best treatment regimen to reduce toxicity and long-term follow-up is still needed.

SYSTEMIC LUPUS ERYTHEMATOSUS
men) with SLE refractory to standard immunosuppressive therapies and either organ- or life-threatening visceral involvement in a single-arm trial. All subjects had at least 4 of 11 American College of Rheumatology criteria for SLE and required more than 20 mg/d of prednisone or its equivalent, despite the use of cyclophosphamide. Patients underwent autologous HCT following a lymphoablative conditioning regimen. Two patients died after mobilization, yielding a treatment-related mortality rate of 4% (2/50). After a mean follow-up of 29 months (range, 6 months to 7.5 years), the 5-year OS rate was 84%, and the probability of disease-free survival rate was 50%. Several parameters of SLE activity improved, including renal function, SLE Disease Activity Index score, antinuclear antibody, anti-double stranded DNA, complement C3 and C4 levels, and carbon monoxide diffusion lung capacity. The investigators suggested these results justified a randomized trial comparing immunosuppression plus autologous HCT with continued standard of care.

Song et al (2011) reported on the efficacy and toxicity of autologous HCT for 17 patients with SLE after 7 years follow-up. OS and PFS rates were used to assess the efficacy and toxicity levels of the treatment. The median follow-up was 89 months (range, 33-110 months). The probabilities of 7-year OS and PFS were 82.4% (SD=9.2%) and 64.7% (SD=11.6%), respectively. The principal adverse events included allergy, infection, elevated liver enzymes, bone pain, and heart failure. Two patients died, one due to severe pneumonia and the other due to heart failure at 33 and 64 months after transplantation, respectively. The authors concluded that their 7-year follow-up results suggested that autologous HCT was beneficial for SLE patients.

Leng et al (2017) reported on 24 patients with severe SLE who received high-dose immunosuppressive therapy and HCT. Patients were followed for 10 years. One patient died following treatment. At the 6-month follow-up, 2 patients had achieved partial remission, and 21 patients had achieved remission. At the 10-year follow-up, the OS rate was 86%; 16 patients remained in remission, 4 were lost to follow-up, 2 patients had died, and 1 patient had active disease.

Section Summary: Systemic Lupus Erythematosus
Evidence for the use of autologous HCT to treat patients with SLE consists of several case series (total N=91 patients). A 4% treatment-related mortality rate was reported in 2 studies. High rates of remission were reported at 6 months, and at 2- to 10-year follow-ups. While HCT has shown beneficial effects on patients with SLE, further investigation of more patients is needed.

JUVENILE IDIOPATHIC OR RHEUMATOID ARTHRITIS
A 2008 review article by Saccardi et al on HCT for autoimmune diseases has summarized the experience with juvenile idiopathic arthritis and rheumatoid arthritis as follows. More than 50 patients with juvenile idiopathic arthritis have been reported to the EBMT Registry. The largest cohort study initially used a single conditioning regimen and, thereafter, a modified protocol. Overall drug-free remission rate was approximately 50%. Some late relapses have been reported, and only partial correction of growth impairment has been seen. The frequency of HCT for rheumatoid arthritis has decreased significantly since
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

2000, due to the introduction of new biologic therapies. Most patients who have undergone HCT have had persistence or relapse of disease activity within 6 months of transplant.

Section Summary: Juvenile Idiopathic or Rheumatoid Arthritis
Evidence for the use of HCT on patients with juvenile idiopathic arthritis consists of data from an EBMT Registry (N>50). Different conditioning regimens were used among the patients, with remission rates averaging 50%. However, relapse has been reported within 6 months in many cases, and new biologic therapies are available for these patients.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Several review articles have summarized experience with HCT in the treatment of chronic inflammatory demyelinating polyneuropathy. In general, the evidence includes a few case reports describing outcomes for autologous HCT in patients who failed standard treatments such as corticosteroids, intravenous immunoglobulins, and plasma exchange. While improvements were reported, some with long-term follow-up, the numbers of patients undergoing the procedure are small, and the potential for serious adverse events is a concern.

Section Summary: Chronic Inflammatory Demyelinating Polyneuropathy
Evidence for the use of HCT to treat patients with chronic inflammatory demyelinating polyneuropathy consists of case reports. Additional investigations are needed due to the toxicity associated with this procedure.

TYPE 1 DIABETES
Systematic Reviews
In 2016, El-Badawy and El-Badri published a meta-analysis on the use of HCT to treat diabetes. The literature search, conducted through August 2015, identified 22 studies for inclusion. Fifteen of the studies (n=300 patients) involved patients with type 1 diabetes; 7 studies (n=224 patients) involved patients with type 2 diabetes. The quality of the selected studies was assessed using criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. The following items were evaluated to determine the risk of bias: attrition, confounding measurement, intervention, performance, selection, and conflict of interest. The mean follow-up in the studies ranged from 6 to 48 months (median, 12 months). Comparisons of C-peptide levels and hemoglobin A1c levels after 12-month follow-up were calculated by type of diabetes (1 or 2) and source of stem cells (see Table 1). Adverse events were reported in 22% of the patients, with no reported mortality. Reviewers concluded that remission of diabetes is possible and safe with stem-cell therapy, patients with previously diagnosed ketoacidosis are not good candidates for HCT, and that early-stage patients may benefit more from HCT. Large-scale well-designed randomized studies considering stem-cell type, cell number, and infusion method is needed.

Table 1. Standard Mean Differences From Baseline in C-Peptide and HbA1c Levels in Patients With Diabetes Treated With HCT After 12 Months of Follow-Up

<table>
<thead>
<tr>
<th>Diabetes</th>
<th>No. of Patients</th>
<th>SMD (95% CI)</th>
<th>No. of Patients</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
</table>

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 12 of 20
Case Series
Several case series evaluated autologous HCT in patients with new-onset type 1 diabetes; there were no published comparative studies. Although a substantial proportion of patients tended to become insulin-free after HCT, remission rates were high.

In 2016, Cantu-Rodriguez et al published a study of 16 patients with type 1 diabetes who received a less toxic conditioning regimen and transplantation. The outpatient procedures were completed without severe complications. At the 6-month follow-up, 3 (19%) were nonresponders, 6 (37%) partially independent from insulin, and 7 (44%) were completely independent of insulin. Hemoglobin A1c levels decreased by a mean of -2.3% in the insulin-independent group.

In 2015, Xiang et al published data on 128 patients ages 12 to 35 years who had been diagnosed with type 1 diabetes no more than 6 weeks before study enrollment. After a mean follow-up of 28.5 months (range, 15-38 months), 71 (55%) patients were considered to be insulin-free. These patients had a mean remission period of 14.2 months. The other 57 (45%) patients were insulin-dependent. The latter group included 27 patients with no response to treatment and another 30 patients who relapsed after a transient remission period. Adverse events included ketoacidosis and renal dysfunction (1 patient each); there was no transplant-related mortality. In multiple logistic regression analysis, factors independently associated with becoming insulin-free after autologous HCT were younger age at onset of diabetes, lower tumor necrosis factor α levels, and higher fasting C-peptide levels.

A 2016 case series by Snarski et al reported on 24 patients with a diagnosis of type 1 diabetes who underwent autologous HCT. Mean age was 26.5 years (range, 18-34 years). After treatment, 20 (87%) of
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy #  00050
Original Effective Date:  01/28/2002
Current Effective Date:  12/20/2017

23 patients went into diabetes remission, defined as being insulin-free with normoglycemia for at least 9.5 months. The median time of remission was 31 months (range, 9.5-80 months). Mean insulin doses remained significantly lower than baseline doses at 2 and 3 years, but the insulin doses returned to pre-HCT levels at years 4 and 5. Among 20 patients remaining in follow-up at the time of data analysis for publication, 4 (20%) remained insulin-free. Adverse events include neutropenic fever in 12 (50%) patients. There were 4 cases of sepsis, including a fatal case of Pseudomonas aeruginosa sepsis. There was also 1 case of pulmonary emphysema after insertion of a central venous catheter.

In 2009, Couri et al reported on the results of a prospective case series evaluating autologous HCT in 23 patients with type 1 diabetes (age range, 13-31 years) diagnosed in the 6 weeks before transplant based on clinical findings including hyperglycemia and confirmed by measurement of serum levels of antigliutamic acid decarboxylase antibodies. At a mean follow-up of 29.8 months (range, 7-58 months) after autologous nonmyeloablative HCT, C-peptide levels increased significantly (C-peptide measures islet cell mass, and an increase after HCT indicates preservation of islet cells), and most patients achieved insulin independence with good glycemic control. Twenty patients without previous ketoacidosis and not receiving corticosteroids during the preparative regimen became insulin-free. Twelve patients maintained insulin independence for a mean of 31 months (range, 14-52 months), and 8 patients relapsed and resumed low-dose insulin. In the continuously insulin-independent group, hemoglobin A1c levels were less than 7.0%. There was no transplant-related mortality.

**Section Summary: Type 1 Diabetes**
Evidence for the use of HCT to treat diabetes consists of several case series and a meta-analysis of 22 studies. The meta-analysis revealed that HCT is more effective in patients with type 1 diabetes and when the treatment is administered soon after the diagnosis. Certain factors limit the conclusions that can be drawn about the overall effectiveness of HCT to treat diabetes; those factors are: heterogeneity in the stem-cell types, cell number infused, and infusion methods.

**OTHER AUTOIMMUNE DISEASES**
Phase 2/3 protocols are being developed for Crohn disease. For the remaining autoimmune diseases (eg, immune cytopenias, relapsing polychondritis), sample sizes are too small to draw conclusions.

A case series of 7 patients with myasthenia gravis was reported by Bryant et al (2016). Using the Myasthenia Gravis Foundation of America clinical classification, all patients achieved complete stable remission, with follow-up from 29 to 149 months. The authors concluded that these positive long-term results warranted further investigation of HCT for patients with myasthenia gravis.

**Section Summary: Other Autoimmune Diseases**
Evidence for the use of HCT for other autoimmune diseases consists of small retrospective studies. Information from larger prospective studies is needed.
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

SUMMARY OF EVIDENCE
For individuals with multiple sclerosis who receive hematopoietic cell transplantation (HCT), the evidence includes a RCT and several case series. Relevant outcomes are overall survival, health status measures, quality of life, and treatment-related mortality and morbidity. The phase 2 RCT compared HCT with mitoxantrone, and the trial reported intermediate outcomes (number of new T2 magnetic resonance imaging lesions); the group randomized to HCT developed significantly fewer lesions than the group receiving conventional therapy. The findings of the case series revealed improvements in clinical parameters following HCT compared with baseline. Adverse event rates were high, and most studies reported treatment-related deaths. Controlled trials (with appropriate comparator therapies) that report on clinical outcomes are needed to demonstrate efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with systemic sclerosis/scleroderma who receive HCT, the evidence includes RCTs and observational studies. Relevant outcomes are overall survival, symptoms, health status measures, quality of life, and treatment-related mortality and morbidity. The results of the ASTIS trial (N=156) have suggested high-dose chemotherapy plus autologous HCT might improve survival among patients with diffuse cutaneous systemic sclerosis compared with pulsed intravenous cyclophosphamide. However, analysis of the internal validity of the trial using U.S. Preventive Services Task Force criteria showed fatal flaws and a poor study rating due to attrition in the control group that could have skewed the survival curve to show better survival for HCT recipients than for controls. A smaller RCT (N=19) found that the rate of improvement at 12 months was significantly higher in the HCT group than in the conventional therapy group. Data from these trials, however, are inconclusive, and additional studies are needed to confirm safety and efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with systemic lupus erythematosus who receive HCT, the evidence includes case series. Relevant outcomes are overall survival, symptoms, quality of life, and treatment-related mortality and morbidity. Several case series (total N=91 patients) have been published. The largest series (N=50) reported an overall 5-year survival rate of 94% and the probability of disease-free survival was 50%. Additional data are needed from controlled studies to demonstrate efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with juvenile idiopathic or rheumatoid arthritis who receive HCT, the evidence includes registry data. Relevant outcomes are symptoms, quality of life, medication use, and treatment-related mortality and morbidity. The registry included 50 patients with juvenile idiopathic or rheumatoid arthritis. The overall drug-free remission rate was approximately 50%. Additional data are needed from controlled studies to demonstrate efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with chronic inflammatory demyelinating polyneuropathy who receive HCT, the evidence includes case reports. Relevant outcomes are overall survival, symptoms, health status measures, quality
of life, and treatment-related mortality and morbidity. Additional data are needed from controlled studies to
demonstrate efficacy. The evidence is insufficient to determine the effects of the technology on health
outcomes.

For individuals with type 1 diabetes who receive HCT, the evidence includes case series and a meta-
analysis of 22 studies. Relevant outcomes are overall survival, symptoms, health status measures, quality
of life, and treatment-related mortality and morbidity. While a substantial proportion of patients tended to
become insulin-free after HCT, remission rates were still high. The meta-analysis further revealed that HCT
is more effective in patients with type 1 diabetes and when HCT is administered soon after the diagnosis.
Certain factors limit the conclusions that can be drawn about the overall effectiveness of HCT in treating
diabetes; those factors are: heterogeneity in the stem cell types, cell number infused, and infusion methods.
The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with other autoimmune diseases (eg, Crohn disease, immune cytopenias, relapsing
polychondritis) who receive HCT, the evidence includes small retrospective studies. Relevant outcomes are
overall survival, symptoms, health status measures, quality of life, and treatment-related mortality and
morbidity. Additional data are needed from controlled studies to demonstrate efficacy. The evidence is
insufficient to determine the effects of the technology on health outcomes.

References

Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017


©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017


Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/06/2001</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/28/2002</td>
<td>Managed Care Advisory Council approval</td>
</tr>
<tr>
<td>06/24/2002</td>
<td>Format revision. No substance change to policy.</td>
</tr>
<tr>
<td>05/07/2004</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>05/18/2004</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>06/28/2004</td>
<td>Managed Care Advisory Council approval</td>
</tr>
<tr>
<td>06/07/2006</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>06/21/2006</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>08/06/2008</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>08/20/2008</td>
<td>Medical Policy Committee approval. No change to coverage eligibility.</td>
</tr>
<tr>
<td>08/06/2009</td>
<td>Medical Policy Committee approval. No change to coverage eligibility.</td>
</tr>
<tr>
<td>08/26/2009</td>
<td>Medical Policy Implementation Committee approval. No change to</td>
</tr>
<tr>
<td></td>
<td>coverage eligibility. Title changed</td>
</tr>
<tr>
<td>07/01/2010</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>07/21/2010</td>
<td>Medical Policy Implementation Committee approval. No change to</td>
</tr>
<tr>
<td></td>
<td>coverage eligibility.</td>
</tr>
<tr>
<td>07/07/2011</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>07/20/2011</td>
<td>Medical Policy Implementation Committee approval. Added indications</td>
</tr>
<tr>
<td></td>
<td>of juvenile idiopathic arthritis and diabetes mellitus to policy</td>
</tr>
<tr>
<td></td>
<td>statement as investigational.</td>
</tr>
<tr>
<td>06/28/2012</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>07/27/2012</td>
<td>Medical Policy Implementation Committee approval. Coverage</td>
</tr>
<tr>
<td></td>
<td>eligibility unchanged.</td>
</tr>
<tr>
<td>03/04/2013</td>
<td>Coding update</td>
</tr>
<tr>
<td>08/01/2013</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>08/21/2013</td>
<td>Medical Policy Implementation Committee approval. Coverage</td>
</tr>
<tr>
<td></td>
<td>eligibility unchanged.</td>
</tr>
<tr>
<td>09/04/2014</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>09/17/2014</td>
<td>Medical Policy Implementation Committee approval. Chronic inflammatory</td>
</tr>
<tr>
<td></td>
<td>demyelinating polyneuropathy added as investigational.</td>
</tr>
<tr>
<td>08/03/2015</td>
<td>Coding update: ICD10 Diagnosis code section added; ICD9 Procedure</td>
</tr>
<tr>
<td></td>
<td>code section removed.</td>
</tr>
<tr>
<td>12/03/2015</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>12/16/2015</td>
<td>Medical Policy Implementation Committee approval. Coverage</td>
</tr>
<tr>
<td></td>
<td>eligibility unchanged.</td>
</tr>
<tr>
<td>12/01/2016</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>12/21/2016</td>
<td>Medical Policy Implementation Committee approval. Coverage</td>
</tr>
<tr>
<td></td>
<td>eligibility unchanged.</td>
</tr>
<tr>
<td>01/01/2017</td>
<td>Coding update: Removing ICD-9 Diagnosis Codes</td>
</tr>
<tr>
<td>12/07/2017</td>
<td>Medical Policy Committee review</td>
</tr>
</tbody>
</table>

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Autoimmune Diseases

Policy # 00050
Original Effective Date: 01/28/2002
Current Effective Date: 12/20/2017

12/20/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged. The word stem removed from title and body of policy.
06/13/2018 Coding update
Next Scheduled Review Date: 12/2018

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2140, S2142, S2150</td>
</tr>
</tbody>
</table>
### Hematopoietic Cell Transplantation for Autoimmune Diseases

**Policy #** 00050  
**Original Effective Date:** 01/28/2002  
**Current Effective Date:** 12/20/2017

<table>
<thead>
<tr>
<th>Code Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>E13.3511-E13.3599</td>
</tr>
<tr>
<td>E13.36-E13.39</td>
</tr>
<tr>
<td>E13.37X1-E13.37X9</td>
</tr>
<tr>
<td>E13.40-E13.49</td>
</tr>
<tr>
<td>E13.51-E13.59</td>
</tr>
<tr>
<td>E13.610-E13.618</td>
</tr>
<tr>
<td>E13.620-E13.628</td>
</tr>
<tr>
<td>E13.630-E13.638</td>
</tr>
<tr>
<td>E13.641-E13.649</td>
</tr>
<tr>
<td>E13.65-E13.69</td>
</tr>
<tr>
<td>E13.8-E13.9</td>
</tr>
<tr>
<td>G35</td>
</tr>
<tr>
<td>M05.00-M05.079</td>
</tr>
<tr>
<td>M05.09-M05.10</td>
</tr>
<tr>
<td>M05.111-M05.179</td>
</tr>
<tr>
<td>M05.19-M05.20</td>
</tr>
<tr>
<td>M05.211-M05.279</td>
</tr>
<tr>
<td>M05.29-M05.30</td>
</tr>
<tr>
<td>M05.311-M05.379</td>
</tr>
<tr>
<td>M05.39</td>
</tr>
<tr>
<td>M05.60</td>
</tr>
<tr>
<td>M05.611-M05.679</td>
</tr>
<tr>
<td>M05.69</td>
</tr>
<tr>
<td>M06.1</td>
</tr>
<tr>
<td>M06.4</td>
</tr>
<tr>
<td>M08.00</td>
</tr>
<tr>
<td>M08.011-M08.079</td>
</tr>
<tr>
<td>M08.08-M08.09</td>
</tr>
<tr>
<td>M08.20</td>
</tr>
<tr>
<td>M08.211-M08.279</td>
</tr>
<tr>
<td>M08.28-M08.29</td>
</tr>
<tr>
<td>M08.3</td>
</tr>
<tr>
<td>M08.40</td>
</tr>
<tr>
<td>M08.411-M08.479</td>
</tr>
<tr>
<td>M08.48</td>
</tr>
<tr>
<td>M08.80</td>
</tr>
<tr>
<td>M08.811-M08.879</td>
</tr>
<tr>
<td>M08.88-M08.90</td>
</tr>
<tr>
<td>M08.911-M08.979</td>
</tr>
<tr>
<td>M08.98-M08.99</td>
</tr>
<tr>
<td>M12.00</td>
</tr>
<tr>
<td>M12.011-M12.079</td>
</tr>
<tr>
<td>M12.08-M12.09</td>
</tr>
<tr>
<td>M32.0</td>
</tr>
<tr>
<td>M32.10-M32.19</td>
</tr>
<tr>
<td>M32.8-M32.9</td>
</tr>
<tr>
<td>M34.0-M34.2</td>
</tr>
<tr>
<td>M34.81-M34.89</td>
</tr>
<tr>
<td>M34.9</td>
</tr>
</tbody>
</table>

*Investigational — A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or

3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.